Products for Research Use Only

Levodropropizine-d5

CAT: 0804-HY-B1895S1Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1895S1Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Levodropropizine-d5 ((S) - (-) -Dropropizine-d5) is deuterium labeled Levodropropizine. Levodropropizine (DF-526) is an orally active histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive agent[1].
Product Name Alternative
(S) - (-) -Dropropizine-d5; DF-526-d5
UNSPSC
12352005
Target
Histamine Receptor; Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Inflammation/Immunology; Neurological Disease
Smiles
OC[C@@H](O)CN1CCN(C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])CC1
Molecular Formula
C13H15D5N2O2
Molecular Weight
241.34
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Luo YL, et al. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure. Inflamm Res. 2013 Dec;62 (12) :1053-61.|[3]Erdogan MA, et al. Levodropropizine suppresses seizure activity in rats with pentylenetetrazol-induced epilepsy. Epilepsy Res. 2019 Feb;150:32-37. |[4]Yamawaki I, et al. Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea. Eur J Pharmacol. 1993 Oct 12;243 (1) :1-6. |[5]Zanasi A, et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015 May 31;10 (1) :19.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products